Spatiotemporal Proteomic Profiling of Huntington’s Disease Inclusions Reveals Widespread Loss of Protein Function

Graphical Abstract

Highlights

- Spatiotemporally resolved brain proteome of wild-type and HD mice
- Quantitative characterization of huntingtin inclusion bodies in vivo
- Sequestration correlates with protein expression levels and specific sequence features
- Resupplying sequestered proteins ameliorates HTT-induced toxicity and inclusion size

Authors
Fabian Hosp, Sara Gutiérrez-Ángel, Martin H. Schaefer, ..., Rüdiger Klein, Irina Dudanova, Matthias Mann

Correspondence
idudanova@neuro.mpg.de (I.D.), mmann@biochem.mpg.de (M.M.)

In Brief
Hosp et al. use quantitative proteomics to describe the soluble and insoluble proteome of several brain regions in a mouse model of Huntington’s disease at various stages of disease progression. Their findings suggest that widespread sequestration of proteins into mutant huntingtin inclusion bodies contributes to HD pathogenesis.

Data and Software Availability
PXD004973

Hosp et al., 2017, Cell Reports 21, 2291–2303
November 21, 2017 © 2017 The Authors.
https://doi.org/10.1016/j.celrep.2017.10.097
Spatiotemporal Proteomic Profiling of Huntington’s Disease Inclusions Reveals Widespread Loss of Protein Function

Fabian Hosp,1,9 Sara Gutiérrez-Ángel,2,3 Martin H. Schaefer,3,4 Jürgen Cox,5 Felix Meissner,9 Mark S. Hipp,7,8 F.-Ulrich Hartl,7,8 Rüdiger Klein,2,9 Irina Dudanova,2,9 and Matthias Mann1,10,*

1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
2Department Molecules-Signaling-Development, Max Planck Institute of Neurobiology, Am Klopferspitz 18, 82152 Martinsried, Germany
3EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Dr. Aiguader 88, 08003 Barcelona, Spain
4Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
5Computational Systems Biochemistry Laboratory, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
6Experimental Systems Immunology Laboratory, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
7Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
8Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany
9These authors contributed equally
10Lead Contact
*Correspondence: idudanova@neuro.mpg.de (I.D.), mmann@biochem.mpg.de (M.M.)
https://doi.org/10.1016/j.celrep.2017.10.097

SUMMARY

Aggregation of polyglutamine-expanded huntingtin exon 1 (HttEx1) in Huntington’s disease (HD) proceeds from soluble oligomers to late-stage inclusions. The nature of the aggregates and how they lead to neuronal dysfunction is not well understood. We employed mass spectrometry (MS)-based quantitative proteomics to dissect spatiotemporal mechanisms of neurodegeneration using the R6/2 mouse model of HD. Extensive remodeling of the soluble brain proteome correlated with insoluble aggregate formation during disease progression. In-depth and quantitative characterization of the aggregates uncovered an unprecedented complexity of several hundred proteins. Sequestration to aggregates depended on protein expression levels and sequence features such as low-complexity regions or coiled-coil domains. In a cell-based HD model, overexpression of a subset of the sequestered proteins in most cases rescued viability and reduced aggregate size. Our spatiotemporally resolved proteome resource of HD progression indicates that widespread loss of cellular protein function contributes to aggregate-mediated toxicity.

INTRODUCTION

Cellular environment is characterized by very high protein concentrations, increasing the danger of aggregation. Thus, maintenance of protein solubility is a fundamental aspect of cellular homeostasis. Aggregates play a prominent role in many neurodegenerative diseases (NDDs) (Ross and Poirier, 2004). Misfolding and aggregation can disrupt cellular function in two ways, loss of endogenous protein function or gain of a novel toxic function, and there is evidence that both processes occur in disease (Winkhofer et al., 2008). The aggregation cascade involves multiple intermediate conformations, such as globular and fibrillar structures, up to the late-stage inclusion bodies (IBs) (Knowles et al., 2014).

Huntington’s disease (HD) is an autosomal dominant NDD characterized by neuropsychiatric and motor impairments (Saudou and Humbert, 2016). It is caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene, which leads to an expanded polyglutamine (polyQ) stretch in the N terminus of the huntingtin protein (The Huntington’s Disease Collaborative Research Group, 1993). A hallmark of this disorder is the appearance of cytoplasmic and intranuclear huntingtin aggregates—so-called inclusion bodies (IBs) (Knowles et al., 2014).

Obtaining insights into the composition of huntingtin IBs is of particular importance in understanding HD mechanisms. So far, it has been challenging to characterize the protein composition of IBs, because they remain insoluble even in very high detergent concentrations. Efforts to purify late-stage polyQ aggregates culminated in the identification of only a few tens of proteins, mainly heat shock factors (Mitsui et al., 2002), components of the ubiquitin-proteasome pathway (Doi et al., 2004), and certain transcription factors (Doi et al., 2004; Shimohata et al., 2000). Given the size of the IBs—up to several micrometers (Gutekunst et al., 1999)—it is likely that they contain far more proteins. Moreover, the quantitative composition of IBs and its variation among brain regions is almost entirely unknown.

Mass spectrometry (MS)-based quantitative proteomics is powerful technology for systems-wide analysis of complex cellular processes (Aebersold and Mann, 2016). To date,
proteomic approaches exploring HD pathogenesis have focused either on expression level changes or on soluble huntingtin inter-
actions (Culver et al., 2012; Langfelder et al., 2016; Shirasaki et al., 2012). In contrast, knowledge of the interplay between sol-
uble and insoluble aspects of the proteome is limited (Baldo et al., 2012), particularly when following disease progression
over time and in differentially affected brain regions.

Here, we investigate molecular neurodegeneration signatures in a mouse HD model by MS-based quantitative proteomics with
spatiotemporal resolution. We describe the soluble and insoluble proteomes of four brain regions, as well as the cerebrospinal
fluid proteome at three time points of disease progression. Acid-based hydrolysis of the aggregates allows us to charac-
terize them in depth by quantitative MS. Our data enable compa-
rison of the degree of protein sequestration from the soluble
pool to IBs over time, as well as analysis of sequence features
of the sequestered proteins. Functional follow-up in a cellular
HD model reveals that increasing expression levels of seques-
tered proteins in many cases restores cellular function and alters
the nature of HttEx1 aggregates, suggesting that widespread
loss of protein function due to sequestration contributes to HD
pathogenesis.

RESULTS

R6/2 transgenic mice express N-terminal exon 1 of polyQ-
expanded huntingtin under control of the human huntingtin pro-
moter (Mangiarni et al., 1996). For our analysis of neurodegener-
ation-associated proteome changes, we selected an early time
point at 5 weeks, before disease onset; an intermediate time
point at 8 weeks, on the verge of visible motor deficits; and a
late time point at 12 weeks, at the end of the lifespan of R6/2
mice (Carter et al., 1999; Davies et al., 1997). We prepared solu-
ble and insoluble extracts from four brain regions (striatum, cortex, hippocampus, and cerebellum), which show differential
vulnerability to HD, with striatum being most severely affected
and cerebellum remaining relatively spared until advanced
disease stages (Vonsattel and DiFiglia, 1998). To relate the
proteome changes in the brain to those in a proximal body fluid,
cerebrospinal fluid was also analyzed (Figure 1).

Spatiotemporal Brain Proteome Resource of Wild-
Type Mice

Recently, we compiled an in-depth cell-type- and region-spe-
cific proteomic catalog of the adult mouse brain with a depth of ~13,000 proteins (Sharma et al., 2015). Building on that analysis by using the peptide identifications as a library (Supple-
mental Experimental Procedures), we now identified 12,498
proteins in the soluble proteome alone using single-run liquid chromatography-tandem mass spectrometry (LC-MS/MS). Of
these, we chose 8,455 proteins by stringent filtering for valid
values (Figure 2A; Table S1A; Supplemental Experimental
Procedures). Correlation analysis indicated a high degree of
reproducibility between replicates (R = 0.84 overall; R = 0.90
for biological replicates) (Figure S1A). First, we investigated the
soluble proteome of wild-type (WT) controls. Protein abun-
dances spanned seven orders of magnitude, with only 217 pro-
teins amounting to 50% of the total protein mass (Figure 2A).
Gene Ontology (GO) biological processes correlated with overall
protein abundances in expected ways (Figure 2A; Table S1A; Supplemental Experimental Procedures). Correlation analysis indicated a high degree of reproducibility between replicates (R = 0.84 overall; R = 0.90
for biological replicates) (Figure S1A). First, we investigated the
soluble proteome of wild-type (WT) controls. Protein abun-
dances spanned seven orders of magnitude, with only 217 pro-
teins amounting to 50% of the total protein mass (Figure 2A).
et al., 2014), presumably reflecting evolutionary constraints on biosynthesis costs (Warringer and Blomberg, 2006). Our approach uncovered several brain region-specific protein clusters (Lein et al., 2007; Sharma et al., 2015). For instance, proteins involved in dopaminergic signaling were enriched in the striatum, which receives extensive dopaminergic innervation (Figure 2C; Table S1D) (Gerfen and Surmeier, 2011). As expected for the narrow time window of the analysis compared to the lifespan of WT animals, little changes in protein expression were detected at different time points (Figure S1B) (Walther and Mann, 2011). Collectively, our soluble brain region data of WT mice provide a comprehensive resource for the community, with copy numbers and spatiotemporal resolution for almost 8,500 proteins.

**Extensive Brain Proteome Remodeling during Disease Progression in R6/2 Mice**

Principal-component analysis (PCA) on the spatiotemporally resolved soluble proteomes of R6/2 and WT mice showed clear separation of samples with two major effects (Figure 3A). First, R6/2 mice after disease onset (8 and 12 weeks) were separated from other samples, reflecting extensive protein remodeling during pathogenesis (Figure 3A). Second, cerebellar proteomes were strongly separated from other brain regions. Only a few proteins were responsible for driving separation in the PCA (Figure 3B) and genotype separately, indicating that age and genotype jointly drove the extensive proteome remodeling in our dataset. To investigate spatiotemporal changes of the soluble proteome in more detail, we tested for differences in any functional annotations associated with the background protein distribution and observed that protein annotations changed spatiotemporally and in accordance with known features of HD progression (Figure S2B; Supplemental Experimental Procedures) (Seiger et al., 2012). One example is the increased expression of proteins involved in neurotransmitter secretion at early disease stages in hippocampus and striatum (8 weeks) followed by a decrease at later stages (12 weeks) (Chen et al., 2013). Another finding is the loss of protein expression associated with the calcineurin complex in the cortex (Gratuz et al., 2015). We have compiled a list of annotation changes across brain regions and time (Table S1E) and find many potentially interesting clues for the selective spatial disease progression, such as reduced cortical expression of annotations associated with amino acid import and ion transmembrane transporter activity or reduced striatal expression of annotations associated with mRNA splicing (Figure S2B). Hence, our dataset provides a rich resource of brain region-specific changes in R6/2 mice to formulate testable hypotheses about HD pathogenesis.

Expression profiles of R6/2 and WT animals at 5 weeks were largely identical, although specific protein clusters already exhibited different expression (Figure 3C). Just three weeks later, expression of mutant HttEx1 caused extensive remodeling of the proteome with marked up- and downregulation of thousands of proteins (Figure 3C, colored clusters). The two upregulated clusters were enriched in proteins of the chaperonin containing TCP1 complex (cluster 2, p < 2.0E−4, BH-FDR) and proteasome accessory complex (cluster 3, p < 4.0E−3), whereas the two downregulated clusters were enriched in proteins associated with the ribosome (cluster 1, p < 9.5E−4) and energy transport.
across the mitochondrial electron transfer chain (cluster 4, p < 9.0E-04) (Table S1F). This is consistent with the deficient energy metabolism and impairment of the ubiquitin-proteasome system in HD (Acuña et al., 2013; Ortega and Lucas, 2014). Our analysis now provides the underlying protein changes in the R6/2 model on a proteome-wide scale.

A hallmark of HD neuropathology is the selective degeneration of striatal medium spiny neurons (MSNs), which has been linked to transcriptional dysregulation of cyclic AMP (cAMP) and CREB signaling (Vonsattel and DiFiglia, 1998; Wyttenbach et al., 2001). We found Pde10a, a cAMP or cyclic guanosine monophosphate (cGMP)-hydrolyzing enzyme highly enriched in MSNs, to be markedly downregulated in R6/2 striatum (Figure 3D). It is one of the earliest and most significantly downregulated gene products in HD patients and a promising target to restore cyclic nucleotide (cNMP) signaling in affected neurons (Giampaò et al., 2010). Furthermore, Pde10a ligands are used in positron emission tomography (PET) to assess the extent of disease and predict conversion to HD (Russell et al., 2014).

We next asked whether other proteins follow the same profile and thus might serve as markers of HD progression. Following the Euclidean distance of the top 20 expression profiles most similar to Pde10a over time and across brain regions; gray boxes indicate striatal expression (upper panel). Boxplots of Z-scored MaxLFQ intensities for the striatal top 20 set (lower panel). Reduced expression of all targets in R6/2 samples compared to WT. See also Figure S2.

The first group included Pde10a-related Pde1b, as well as Darpp-32, which is widely used as a marker for both MSNs and the attenuation of dopaminergic signaling in HD (Jiang et al., 2011). Further candidates were also associated with dopamine metabolism, such as Drd1, a dopamine receptor expressed in MSNs whose striatal loss correlates with cognitive decline (Chen et al., 2013). Adenylate cyclase 5 (Adcy5) is predominantly expressed in the striatum and has been linked to rarer forms of chorea and dystonia (Carapito et al., 2015). A transcriptomics and proteomics study identified 17 of our 21 potential markers among the top 50 hub genes of a striatal module negatively associated with CAG repeat length in a different HD mouse model (Langfelder et al., 2016). Thus, our data define a set of MSN-specific proteins that can be used to assess cNMP-linked dopaminergic imbalances.

**Inflammatory Profile in the Cerebrospinal Fluid Proteome**

The cerebrospinal fluid is an invaluable source in assessing pathological alterations of the CNS (Kroksveen et al., 2011). We next asked whether HD signatures in the soluble brain proteome correlate with changes in the cerebrospinal fluid. A total of 778 cerebrospinal fluid proteins were quantified with our single-shot workflow after filtering out likely contaminants (Table S2A; Supplemental Experimental Procedures). Unsupervised
hierarchical clustering separated R6/2 and WT samples, indicating changes in protein secretion to the cerebrospinal fluid upon expression of mutant HttEx1 (Figure 4A). Among the most dysregulated proteins we found peptidase regulators increased in the cerebrospinal fluid of R6/2 mice (Figures 4B and 4C; Table S2B). The presence of proteolytic enzymes reflects inflammatory processes, and our data suggest that several members of the cathepsin family dominantly contribute to these processes, because they are major drivers of the PCA separation between R6/2 and WT samples (Ossovskaya and Bunnett, 2004). Finally, we compared correlations of protein expression changes between the brain and the cerebrospinal fluid proteome (Figure 4D). Although expression changes in the brain over time correlated between R6/2 mice (R > 0.5), the correlation between soluble brain proteomes and cerebrospinal fluid was low (R < 0.10) (Figure 4D). This indicates that global expression changes in the soluble proteome are not necessarily reflected in the cerebrospinal fluid proteome.

In-Depth Characterization of the Insoluble Proteome In Vivo

Huntingtin-containing IBs are a hallmark of HD, but the identity and quantity of their constituent proteins are largely unknown. In agreement with previous studies (Davies et al., 1997; Meade et al., 2002), brains of R6/2 mice already displayed widespread IBs at 5 weeks, with striatal IBs being significantly smaller than cortical ones (Figures S3A–S3C).

Although purification of late-stage aggregates is straightforward due to their extreme insolubility, this biophysical property also makes them resistant to proteolytic digestion, a precondition for MS analysis. Concentrated formic acid can dissolve polyQ aggregates (Hazeki et al., 2000; Kim et al., 2016), and here we demonstrate that it is compatible with tissue-based quantitative proteomics (Figure 1; Supplemental Experimental Procedures). This purification approach, when coupled to state-of-the-art MS, identified several hundred proteins and revealed extensive protein sequestration to the insoluble fraction in the R6/2 brain, including endogenous mouse Htt (Figure S4; Table S3). For quantitative analysis of the aggregate composition, we used the iBAQ (intensity-based absolute quantification) algorithm to estimate protein abundances (Schwanhaüser et al., 2011). Only 10 proteins constituted more than 50% and the top 50 proteins constituted more than 75% of the aggregate mass in 12-week-old R6/2 striatum (Figure 5A). Apart from histones and RNA-binding proteins, these included proteins involved in neuronal plasticity, as well as myelin components.

Figure 4. Altered Cerebrospinal Fluid Proteome in R6/2 Mice

(A) Hierarchical clustering of cerebrospinal fluid protein expression reveals good separation of R6/2 and WT mice; row bars indicate filters for known GO annotations related to secretion (see Supplemental Experimental Procedures for details).

(B) PCA projections of all cerebrospinal fluid samples show good separation between WT and R6/2 mice.

(C) Corresponding PCA loadings of (B) reveal strong inflammatory response in R6/2 animals. The color bar displays the 1D annotation score with the two most enriched annotations for R6/2 mice; the annotation score indicates the center of the protein distribution of each significant annotation category relative to the overall distribution of values. p value, BH-FDR corrected.

(D) Correlation of protein expression changes between different disease stages is high within the soluble proteome (purple inlay) but low for the comparison of the soluble proteome with the cerebrospinal fluid (green inlay) of R6/2 mice.

See also Table S2.
Table S3). Co-immunostainings for the myelin protein Plp1, aggregated HttEx1, and a neuronal marker revealed co-localization of Plp1 with aggregated HttEx1 in many neuronal IBs, confirming that myelin proteins are true components of neuronal inclusions (Figures S3D and S3E).

Most sequestered proteins contributed little to overall aggregate mass. There was a general tendency for abundant cellular proteins to also be among the more abundant aggregate proteins (median R = 0.40 across all conditions) (Figure S5). GO analysis revealed many proteins associated with native huntingtin function and the proteostasis network to be enriched in the R6/2 insoluble fraction. All five members of the collapsin response mediator protein (Crmp) family, also known as dihydropyrimidinase-related proteins (Dpysl), were also enriched (Figure 5B). A study identified Crmp1 as a suppressor of huntingtin toxicity (Stroedicke et al., 2015). Apart from confirming these known aggregate constituents, our data provide a large number of new proteins with potential links to HD (Table S3A).

We hypothesized that the extensive soluble proteome remodeling in HD should be reflected in the insoluble proteome. (Table S3). Co-immunostainings for the myelin protein Plp1, aggregated HttEx1, and a neuronal marker revealed co-localization of Plp1 with aggregated HttEx1 in many neuronal IBs, confirming that myelin proteins are true components of neuronal inclusions (Figures S3D and S3E).

Most sequestered proteins contributed little to overall aggregate mass. There was a general tendency for abundant cellular proteins to also be among the more abundant aggregate proteins (median R = 0.40 across all conditions) (Figure S5). GO analysis revealed many proteins associated with native huntingtin function and the proteostasis network to be enriched in the R6/2 insoluble fraction, including known interactors and aggregation modifiers of polyQ-expanded huntingtin. Several members of the TCP-1 ring complex (TRiC) and the Hsp40, Hsp70, and Hsp90 families made up ~1.5% of the insoluble fraction mass. All five members of the collapsin response mediator protein (Crmp) family, also known as dihydropyrimidinase-related proteins (Dpysl), were also enriched (Figure 5B). A study identified Crmp1 as a suppressor of huntingtin toxicity (Stroedicke et al., 2015). Apart from confirming these known aggregate constituents, our data provide a large number of new proteins with potential links to HD (Table S3A).

We hypothesized that the extensive soluble proteome remodeling in HD should be reflected in the insoluble proteome.
Mapping our soluble proteome data to the insoluble fraction revealed a large number of proteins that were downregulated in the soluble proteome and enriched in the aggregates (blue and cyan in Figures 5B and 5C; Figure S4), suggesting widespread loss of protein function by sequestration. Conversely, we also found many proteins that were upregulated in both the soluble and the aggregate proteomes (orange and red in Figures 5B and 5C; Figure S4; Table S3B). Among the latter, the TRiC chaperonin and the GO term “proteasome accessory complex” were highly overrepresented (p < 4.0E−5 and p < 3.2E−3 BH-FDR, respectively) (Table S3E), confirming specific upregulation of chaperones that interact with aggregates but become entangled with them. Potential loss-of-function candidates (reduced in the soluble proteome and increased in the insoluble proteome) often had a significantly higher abundance compared to proteins upregulated in the soluble proteome (Figure S6A), consistent with a sequestration mechanism that depletes the cellular pool of these proteins, thereby impeding cellular function.

Next, we asked whether sequestration into the aggregates correlated with certain biophysical features. We focused on polyQ length, low-complexity regions (LCRs), and coiled-coil domains (CCDs), motifs known to modulate protein aggregation (Fiumara et al., 2010; Kato et al., 2012; Li and Li, 2004; Schaefer et al., 2012). Insoluble fractions from R6/2 striata contained significantly more aggregation-prone proteins than WT controls, with a robust effect size for CCDs and small effect sizes for polyQ and LCRs (Figures 5D–5F; Figures S6B–S6D). In addition, R6/2 samples were significantly enriched for proteins with higher molecular weight (Figure 5G; Figure S6E). Larger proteins tend to be less thermodynamically stable, which may explain why their folding is compromised under conditions of conformational stress (Sharma et al., 2012).

To quantify the degree of sequestration, we estimated absolute protein abundance using the iBAQ algorithm and compared the amount of each protein in the soluble and insoluble proteome (Figure 6A; Figure S6F). Extracellular matrix (ECM) proteins had the least soluble proportion, reflecting their insolubility and demonstrating efficient enrichment of insoluble proteins in our protocol (Figure 6A, marked in red). Endogenous Htt was also recruited into the aggregates (Figure 6A, marked in pink). In concordance with the increase in aggregate size, we observed increased sequestration of protein mass over time, hence progressively depleting the pool of functional proteins. In 8-week-old animals, a full 80% of proteins were at least in a 1:1 ratio in the cortical IBs compared to the soluble pool.

To determine whether the IB composition varies over time and across brain regions, we tested for differences in any functional annotations to the background protein distribution (Figure 6B; Table S3F; Supplemental Experimental Procedures) and found spatiotemporal changes of protein annotations, reflecting many known features of HD pathogenesis. Transcriptional and epigenetic dysregulation is an early event in HD, and we found that IBs at 5 weeks were already significantly enriched in DNA- and chromatin-binding elements (FDR < 0.05). Conversely, late-stage IBs at 8 to 12 weeks were enriched in proteins associated with glutamate receptor signaling and synaptic transmission, correlating with the onset of motor phenotypes (FDR < 0.05, respectively). Similarly, we observed spatial changes such as enrichment of SMAD-binding proteins in cortical IBs (FDR < 0.05), or depletion of proteins involved in Wnt signaling pathways in striatal IBs (FDR < 0.05), linked to synaptic degeneration (Galli et al., 2014). Our proteomic analysis therefore demonstrates that protein sequestration is both brain region and time specific and may link dynamic changes in the IBs to the phenotype.
Overexpressing Loss-of-Function Candidates Rescues PolyQ Length-Dependent Toxicity and Alters IB Size

We identified several hundred proteins that were depleted from the soluble pool and increased in insoluble aggregates. To test whether this represents widespread loss of protein function, we selected a group of 18 candidates for functional follow-up based on several criteria, including their profiles in the proteomics experiments and association with neuronal functions but no previous link to HD (Figure S7A; Table S4). For several candidates, reduction in protein levels in the soluble fraction was confirmed by western blot (Figure 7A; Figure S7B). Among the selected candidates was the amyotrophic lateral sclerosis (ALS)-associated protein hnRNPA2B1. ALS-linked hnRNPA2B1 mutations lead to an accumulation of insoluble protein in the nucleus (Martinez et al., 2016). Immunostaining in R6/2 striatum demonstrated a nuclear accumulation of hnRNPA2B1 in most MSNs, as well as its co-localization with HttEx1 IBs (Figures S7C–S7E).

For the follow-up of the selected proteins, we used inducible neuron-like PC12 cells with stably integrated, GFP-tagged HttEx1 with either 23 or 74 glutamines (HD-Q23 and HD-Q74 cells). Induction of HttEx1 led to polyQ length-dependent cell death (Figure S7F) (Wyttenbach et al., 2001). Quantitative proteomics revealed that all candidates were expressed in this cell line with medium to high abundance (Figure S7G), and induction of HttEx1 did not substantially alter their expression (Figure S7H). Furthermore, in most cases, transfection of a candidate increased its protein levels compared to non-transfected controls (Figure S7I). Overexpression of individual candidates significantly improved the viability of HD-Q74 cells in 12 of 18

Figure 7. Overexpression of Loss-of-Function Candidates Ameliorates HttEx1 Phenotypes

(A) Left: quantification of candidates in immunoblots of 8- and 12-week-old R6/2 striata, normalized to WT (dotted line). Student’s t test, *p < 0.05; n = 3–4. Right: representative examples of immunoblots from 12-week-old striata.

(B) Log2 fold changes (log2FCs) in viability of HD-Q23 (upper panel) or HD-Q74 (lower panel) cells transfected with the candidates as measured by lactate dehydrogenase (LDH) assay. Multiple one-tailed t test with Benjamini-Hochberg correction; *FDR < 0.05, **FDR < 0.01; normalized to mCherry controls; n = 4.

(C) Candidates’ effects on the viability of starved, non-induced HD-Q74 cells. Multiple two-tailed t test with Benjamini-Hochberg correction; *FDR < 0.05; n = 3.

(D) Log2FCs in IB diameter in HD-Q74 cells transfected with the candidates. Multiple two-tailed t test with Benjamini-Hochberg correction; *FDR < 0.05; **FDR < 0.01; normalized to mCherry; n = 3.

(F) Distribution of IB diameter bins in HD-Q74 cells transfected with the candidates. Yellow, <1 μm; orange, 1–2.5 μm; red, >2.5 μm. Multiple two-tailed t test with Benjamini-Hochberg correction; *FDR < 0.05, **FDR < 0.01; n = 3.

(G) Log2FCs in the soluble fraction of proteins after overexpression of candidates in HD-Q74 cells, determined by changes in iBAQ ratios (soluble to insoluble). The red dot indicates the iBAQ ratio of the candidate. Multiple two-tailed t test with Benjamini-Hochberg correction; ***FDR < 0.001; n = 3. NCAM1 was not identified in the insoluble fraction in this experiment.

See also Figure S7.
cases (BH-FDR < 0.05), with a mean survival increase of 40% (Figure 7B, lower panel). Three proteins (Ap2a2, Mapt, and Nfasc) that increased the viability of control HD-Q23 cells (Figure 7B, upper panel) and two proteins that repeatedly exhibited low transfection rates (Dctn1 and Sbf1) were excluded from further analyses. To distinguish between a general effect on cell survival and a specific involvement in mutant HttEx1 toxicity, we tested whether the candidates rescued the viability of non-induced HD-Q74 cells under starvation and observed a rescue with only one protein, Cnp (Figure 7C). Thus, the effects of the remaining candidates were specific for mutant HttEx1 toxicity.

We next asked whether the HttEx1 toxicity-modifying proteins also had an effect on aggregation. Overexpression of the candidates did not change the number of GFP+ foci per cell (Figure S7J) but did reduce their size in 10 of 11 cases (Figure 7D). Moreover, the percentage of small foci (<1 μm in diameter) increased significantly in 8 of the 11 cases, whereas the percentage of large foci (>2.5 μm) was significantly reduced in all cases (Figures 7E and 7F). As an orthogonal approach, we employed membrane filter trap assay, which also did not reveal a significant change in the aggregation load (Figure S7K). Finally, the soluble proportion of most cellular proteins increased significantly after overexpression of the candidates in HD-Q74 cells, as well as, in most cases, the soluble proportion of the candidate (Figure 7G). Thus, overexpression of the proteins sequestered to HttEx1 IBs ameliorates mutant HttEx1 toxicity and decreases aggregate size, but not load.

**DISCUSSION**

We applied quantitative proteomics to investigate molecular neurodegeneration signatures in an in vivo model of HD. Employing a recently published proteomic resource of the mouse brain (Sharma et al., 2015) and a single-run LC-MS/MS workflow, we characterized the brain proteome of the R6/2 mice and WT controls to a depth of more than 12,000 proteins. Spatiotemporal characterization of the soluble proteome during disease progression uncovered extensive alterations in brain regions vulnerable to HD. The data provide a resource to the community, which is available via a user-friendly database (http://maxqb.biochem.mpg.de/mxdb/). The value of such data is illustrated by the identification of several MSN-specific proteins whose signaling is compromised in HD and that are already used for PET imaging. These clinically relevant proteins emerge from our analysis and thus validate the R6/2 model, which is one of the best characterized and most widely used HD mouse models. Comparative studies demonstrated its extensive similarity with full-length Huntingtin models at pathological, transcriptional, and electrophysiological levels (Cummins et al., 2009; Langfelder et al., 2016; Woodman et al., 2007). Nevertheless, it will be necessary to extend our approach to full-length models in the future.

Furthermore, our dataset contains a number of additional proteins that have closely related expression regulation in the course of HD, making them promising candidates for imaging or other applications. Another example emerged upon matching the soluble brain and cerebrospinal fluid proteomes. Several proteomic analyses have proposed potential biomarkers of HD progression in cerebrospinal fluid, mostly linked to inflammation (Dalrymple et al., 2007; Fang et al., 2009). Here, we also observed a strong inflammatory signature in the cerebrospinal fluid of R6/2 mice. However, proposed biomarkers have failed to be validated for clinical trials (Byrne and Wild, 2016). We found an overall low correlation between changes in the soluble proteome and the cerebrospinal fluid, which needs to be considered when attempting to identify biomarkers in cerebrospinal fluid.

The use of formic acid to chemically cleave aggregated proteins, in combination with quantitative MS, enabled us to perform the first in-depth characterization of HttEx1 aggregates in vivo and in a stage- and brain region-dependent manner. This generic approach provides an unbiased tool to study insoluble aggregates in other misfolding diseases. In the case of HD, we find that the insoluble fraction containing late-stage HttEx1 aggregates consists of several hundred proteins, concordant with the very large size of IBs in model systems and patients. Just a few proteins, generally only expressed in the brain, make up the bulk of the aggregate mass. This suggests that the aggregate composition in HD, and perhaps in other NDDs, is highly tissue specific. The presence of several myelin-associated proteins was surprising, because these are expressed mainly in glial cells. However, in our recent brain proteome resource (Sharma et al., 2015), as well as in the Human Protein Atlas (Uhlen et al., 2015), myelin was also detected in neurons, and we could confirm the presence of Plp1 in IBs by immunostaining. Therefore, we believe that these proteins derive mostly from neuronal IBs, not from oligodendrocytes.

Few aggregate constituents were known previously, such as proteostasis network components, native huntingtin interactors, and several transcription factors. However, most identified proteins represent diverse biological functions. We found that these proteins are rich in aggregation-prone motifs, such as CCDs or LCRs. CCDs and LCRs are molecular recognition motifs, regulating oligomerization of higher-order structures among both RNAs and proteins (Cumberworth et al., 2013; Kato et al., 2012). CCDs are prominently involved in protein-protein interactions and can interact with polyQ proteins, promoting their aggregation (Fiumara et al., 2010). RNA-binding proteins, which figure prominently in the aggregates, are particularly rich in LCRs, because they can be molecular determinants of RNA granule assembly (Han et al., 2012; Kato et al., 2012). The formation of such reversible structures allows increase of local concentrations of relevant interactors. However, because LCRs also promote protein binding promiscuity and aggregation propensity, this comes at the cost of undesirable, non-productive interactions, leading to several diseases (Cumberworth et al., 2013). We have shown in a cell model of HD that LCR domains co-aggregate with mutant HTT and other LCR-containing proteins, exacerbating aggregate formation (Kim et al., 2016). Our current results suggest that LCRs are also responsible for promoting co-aggregation in vivo. Several elements of the protein folding machinery also contain LCRs (Hageman et al., 2010). It is tempting to speculate that the presence of these sequences in both aggregation-prone and aggregation-counteracting proteins represents a balance that has co-evolved over time.

Our insoluble fraction showed little overlap with recently published protein aggregation sets. Of all insoluble proteins in our dataset, less than 5% overlapped with interactors of artificial
amyloid-like beta sheet proteins (Olzscha et al., 2011), and less than 1% were shared with either RNA-binding proteins containing prion-like domains (Li et al., 2013) or stress granules (Jain et al., 2016). The little overlap between these aggregation-associated proteins indicates that proteins from our insoluble dataset specifically co-aggregate with mutant HttEx1.

The integrative aspect of jointly analyzing the soluble and insoluble proteome, combined with the spatiotemporal resolution, allowed us to elucidate molecular neurodegeneration signatures that have not yet been linked to HD. Hundreds of proteins were downregulated in the soluble proteome and upregulated in the insoluble proteome. This prevalent sequestration of proteins into the aggregates suggests widespread loss of protein function in HD. Although it has been reported that IBs are protective by sequestering toxic soluble oligomers (Arrasate et al., 2004; Haass and Selkoe, 2007), the substantial depletion of soluble proteins observed here suggests a major impairment of protein homeostasis in the cell.

In accordance with this hypothesis, our rescue experiments demonstrated that overexpression of loss-of-function candidates ameliorated HttEx1 toxicity in a cellular HD model. The molecular mechanism underlying the observed increase in cell viability requires further analysis. It is possible that each of the selected candidates is necessary for cell survival and overexpression simply re-supplies the cell with an essential factor. In addition, a protein with a strong affinity for HttEx1 aggregates may occupy much of the aggregates’ interaction surface and thereby reduce sequestration of endogenous proteins, as suggested by the increase of the soluble proportion of most proteins upon transfection of the candidates into HD-Q74 cells. The latter scenario may also explain why many of our candidates reduced IB size. Our data therefore suggest that overexpression of candidate proteins could increase cell viability by interfering with multistage aggregate formation. Soluble interactors of both native and mutant NDD proteins have been identified as disease modifiers (Hosp et al., 2015; Kaltenbach et al., 2007). Most proteins in the insoluble aggregates, however, are most likely not associated with the native function of the disease protein. Given the high proportion of toxicity mediators in our validation set, it is likely that the total set of potential loss-of-function proteins contains further candidates that would be interesting to study in the context of HD.

In summary, we provide a rich resource comprising (1) changes in the proteome upon disease progression, (2) protein copy numbers, (3) degree of protein sequestration to the IBs, and (4) correlation of proteomes across different brain regions, time, and aspects of the brain and cerebrospinal fluid proteome. Altogether, these data paint a quantitative picture of the dynamic aggregate proteome in relation to the brain proteome. This highlights the power of integrative approaches to elucidate molecular mechanisms of HD, helping to bridge the gap between identification of disease-associated pathways and their corresponding phenotypes.

**EXPERIMENTAL PROCEDURES**

Further details and an outline of resources used in this work can be found in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and four tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2017.10.097.

AUTHOR CONTRIBUTIONS

F.H. performed wet lab and MS experiments and analyzed the data. S.G.-A. performed wet lab and imaging experiments and analyzed the data. I.D. performed cerebrospinal fluid extraction and mouse brain dissection. M.H.S. and J.C. developed bioinformatic tools. M.S.H., F.M., and F.-U.H. provided reagents and advised research. F.H., S.G.-A., I.D., R.K., and M.M. interpreted the data. F.H. and M.M. conceived the project and wrote the manuscript. All authors read and approved the manuscript.

ACKNOWLEDGMENTS

We thank our colleagues at the Max Planck Institutes of Biochemistry and Neurobiology, especially G.H.H. Borner and D. Hornburg for help and fruitful discussions; S. Kroiss, K. Mayr, I. Paron, G. Sowa, and B. Splettstösser for excellent technical assistance; and K. Schulz-Triegelaff and the MPIB animal facility for help with the R6/2 breeding and caretaking. We acknowledge the gift of the PC12 HD cell lines from D. Rubinsztein (University of Cambridge, UK). The research leading to these results has received funding from the Munich Cluster for Systems Neurology “Synergy,” the European Research Council Synergy grant “ToPAG—Toxic protein aggregation in neurodegeneration” (ERC-2012-SyG_318987-ToPAG), and the Max Planck Society for the Advancement of Science.

REFERENCES

Acuña, A.I., Esparza, M., Kramm, C., Beltrán, F.A., Parra, A.V., Cepeda, C., Toro, C.A., Vidal, R.L., Hetz, C., Concha, I.I., et al. (2013). A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington's disease in mice. Nat. Commun. 4, 2917.

Aeberson, R., and Mann, M. (2016). Mass-spectrometric exploration of proteome structure and function. Nature 537, 347–355.

Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., and Finkeiner, S. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 437, 805–810.

Baldo, B., Paganetti, P., Grueninger, S., Marcellin, D., Kaltenbach, L.S., Lo, D.C., Semmelroth, M., Zivanovic, A., Abramowski, D., Smith, D., et al. (2012). TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease. Chem. Biol. 19, 264–275.

Byrne, L.M., and Wild, E.J. (2016). Cerebrospinal fluid biomarkers for Huntington's disease. J. Huntington's Dis. 5, 1–13.

Carapito, R., Paul, N., Untrah, M., Le Gentil, M., Ott, L., Alsaeh, G., Jochem, P., Radosavljevic, M., Le Caignec, C., David, A., et al. (2015). A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia. Mov. Disord. 30, 423–427.

Carter, R.J., Lione, L.A., Humby, T., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B., and Morton, A.J. (1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 3248–3257.

Chen, J.Y., Wang, E.A., Cepeda, C., and Levine, M.S. (2013). Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility. Front. Neurosci. 7, 114.

Culver, B.P., Savas, J.N., Park, S.K., Choi, J.H., Zheng, S., Zeitlin, S.O., Yates, J.R., 3rd, and Tanese, N. (2012). Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J. Biol. Chem. 287, 21599–21614.

Cumberworth, A., Lamour, G., Babu, M.M., and Gspother, J. (2013). Promiscuity as a functional trait: intrinsically disordered regions as central players of interacomes. Biochem. J. 454, 361–369.

Cummings, D.M., André, V.M., Uzgil, B.O., Gee, S.M., Fisher, Y.E., Cepeda, C., and Levine, M.S. (2009). Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J. Neurosci. 29, 10371–10386.

Dalymple, A., Wild, E.J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, A., Jackson, G.S., Isaacs, J.D., Kristiansen, M., Bates, G.P., et al. (2007). Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6, 2833–2840.

Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzer, E., Wanker, E.E., Mangiarini, L., and Bates, G.P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537–548.

DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993.

Doi, H., Mitsui, K., Kurosawa, M., Machida, Y., Kuroiwa, Y., and Nukina, N. (2004). Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett. 571, 171–176.

Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N., and Krainc, D. (2002). Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Sci. Cell Reports 5, 2238–2243.

Fang, Q., Strand, A., Law, W., Faca, V.M., Fitzgibbon, M.P., Hamel, N., Houle, B., Liu, X., May, D.H., Poschmann, G., et al. (2009). Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol. Cell. Proteomics 8, 451–466.

Fiumara, F., Fioriti, L., Kandel, E.R., and Hendrickson, W.A. (2010). Essential role of coiled coils for aggregation and activity of Q/N-rich prions and PolyQ proteins. Cell 143, 1121–1135.

Galli, S., Lopes, D.M., Ammari, R., Kopra, J., Millar, S.E., Gibb, A., and Salinas, P.C. (2014). Deficient Wnt signalling triggering striatal synaptic degeneration and impaired motor behaviour in adult mice. Nat. Commun. 5, 4992.

Geiger, T., Wehner, A., Schaab, C., Cox, J., and Mann, M. (2012). Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol. Cell. Proteomics 11, M111.041050.

Gerfen, C.R., and Surmeier, D.J. (2011). Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441–466.

Giampà, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menetti, F.S., and Fusco, F.R. (2010). Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease. PLoS ONE 5, e13417.

Gratze, M., Noël, A., Julien, C., Cisbani, G., Milot-Rousseau, P., Morin, F., Dicker, M., Goupil, C., Bezeau, F., Poitras, I., et al. (2015). Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington’s disease. Hum. Mol. Genet. 24, 86–99.

Gutekunst, C.A., Li, S.H., Yi, H., Mulroy, J.S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R.J., Hersch, S.M., and Li, X.J. (1999). Nuclear and neuronal aggregates in Huntington’s disease: relationship to neuropathology. J. Neurosci. 19, 2522–2534.

Haas, C., and Selkoe, D.J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112.

Hageman, J., Rujano, M.A., van Waarde, M.A., Kampinga, H.H., and Lubsen, N.H. (2010). A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol. Cell 37, 355–369.
Han, T.W., Kato, M., Xie, S., Wu, L.C., Mirzaei, H., Pei, J., Chen, M., Xie, Y., Allen, J., Xiao, G., and McKnight, S.L. (2012). Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell 149, 768–779.

Hazecki, N., Tukamoto, T., Goto, J., and Kanazawa, I. (2000). Formaldehyde inactivating proteins are genetic modifiers of neurodegeneration. PLoS Genet. Kaltenbach, L.S., Romero, E., Becklin, R.R., Chettier, R., Bell, R., Phansalkar, A., Huntingtin's disease through activation of multiple Sirt1 targets. Nat. Med. Z., Cai, H., et al. (2011). Neuroprotective role of Sirt1 in mammalian models of Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H., et al. (2011). Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med. 16, 153–158.

Kaltenbach, L.S., Romero, E., Becklin, R.R., Chettier, R., Bell, R., Phansalkar, A., Strand, A., Torcassi, C., Savage, J., Huriburt, A., et al. (2007). Huntington interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 11, 1351–1362.

Kato, M., Han, T.W., Xie, S., Shi, K., Du, X., Wu, L.C., Mirzaei, H., Goldsmith, E.J., Longgood, J., Pei, J., et al. (2012). Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149, 753–767.

Kim, Y.E., Hosp, F., Frottin, F., Ge, H., Mann, M., Hayer-Hartl, M., and Hartl, F.U. (2016). Soluble oligomers of polyQ-expanded huntingtin target a multiplicity of key cellular factors. Mol. Cell 63, 951–964.

Knowles, T.P., Vendruscolo, M., and Dobson, C.M. (2014). The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384–396.

Kroksveen, A.C., Opsahl, J.A., Aye, T.T., Ulvik, R.J., and Berven, F.S. (2011). Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteome Res. 10, 29–36.

Langerfeld, P., Cantile, J.P., Chatzopoulos, D., Wang, N., Gao, F., Al-Ramahi, I., Lu, X.H., Ramos, E.M., El-Zein, K., Zhao, Y., et al. (2016). Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat. Neurosci. 19, 623–633.

Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A.F., Boguski, M.S., Brockway, K.S., Bynes, E.J., et al. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168–176.

Li, S.H., and Li, X.J. (2004). Huntingtin-protein interactions and the pathogenesis of Huntington’s disease. Trends Genet. 20, 146–154.

Li, Y.R., King, O.D., Shorter, J., and Gitler, A.D. (2013). Stress granules as crosstalk among cellular catabolic pathways in mammalian cells. Cell 87, 493–506.

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrah, H., Davies, S.W., and Bates, G.P. (1996). Xon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 639–649.

Martinez, F.J., Pratt, G.A., Van Nostrand, E.L., Batra, R., Huelga, S.C., Kapeli, K., Freese, P., Chun, S.J., Ling, K., Gelbouin-Burkhart, C., et al. (2016). Protein-RNA networks regulated by normal and ALS-associated mutant HNRNPA2B1 in the nervous system. Neuron 92, 780–795.

Meade, C.A., Deng, Y.P., Fusco, F.R., Del Mar, N., Hersch, S., Goldowitz, D., and Reiner, A. (2002). Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J. Comp. Neurol. 449, 241–269.

Mitsui, K., Nakayama, H., Akagi, T., Nekooki, M., Ohtawa, K., Takio, K., Hashikawa, T., and Nukina, N. (2002). Identification of elongation factor-1alpha and heat shock protein 84 as aggregate-interacting proteins. J. Neurosci. 22, 9267–9277.

Olszach, H., Schermann, S.M., Woeber, A.C., Pinkert, S., Hecht, M.H., Tartaglia, G.G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F.U., and Valabas, R.M. (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67–78.

Orr, H.T., and Zoghbi, H.Y. (2007). Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575–621.

Ortega, Z., and Lucas, J.J. (2014). Ubiquitin-proteasome system involvement in Huntington’s disease. Front. Mol. Neurosci. 7, 77.

Ossovskyaya, V.S., and Bunnett, N.W. (2004). Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84, 579–621.

Ross, C.A., and Poirier, M.A. (2004). Protein aggregation and neurodegenerative disease. Nat. Med. 10 (Supp), S10–S17.

Russell, D.S., Barret, O., Jennings, D.L., Friedman, J.H., Tamagnan, G.D., Thoma, D., Alagille, D., Morley, T.J., Papin, C., Papapetropoulos, S., et al. (2014). The phosphodiesterase 10 postransmission tomography tracer. [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurology. 71, 1520–1528.

Saudou, F., and Humbert, S. (2016). The biology of huntingtin. Neuro 89, 910–926.

Schafer, M.H., Wanner, E.E., and Andrade-Navarro, M.A. (2012). Evolution and function of CAG/polyglutamine repeats in protein-protein interaction networks. Nucleic Acids Res. 40, 4273–4287.

Scheltema, R.A., and Mann, M. (2012). SprayQc: a real-time LC-MS/MS quality control monitoring system to maximize uptime using off the shelf components. J. Proteome Res. 11, 3458–3466.

Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., and Selbach, M. (2011). Global quantification of mammalian gene expression control. Nature 473, 337–342.

Sharma, K., Vabalas, R.M., Macek, B., Pinkert, S., Cox, J., Mann, M., and Hartl, F.U. (2012). Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response. Mol. Cell. Proteomics 11, M111.014654.

Sharma, K., Schmitt, S., Bergner, C.G., Tyasova, S., Kannayaj, N., Manrique-Hoyos, N., Korgi, K., Cantuti, L., Hanisch, U.K., Philips, M.A., et al. (2015). Cell type- and brain region-resolved mouse brain proteome. Nat. Neurosci. 18, 1819–1831.

Shimohata, T., Nakajima, T., Yamada, M., Uchida, C., Onodera, O., Naruse, S., Kimura, T., Koide, N., Nozaki, K., Sano, Y., et al. (2000). Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 26, 29–36.

Shirasaki, D.I., Greiner, E.R., Al-Ramahi, I., Gray, M., Boontheung, P., Geschwind, D.H., Botos, J., Coppola, G., Horvath, S., Loo, J.A., and Yang, X.W. (2012). Network organization of the huntingtin proteome interactome in mammalian brain. Neuron 75, 41–57.

Stroedicke, M., Bounab, Y., Strempel, N., Klockeimer, K., Yigit, S., Friedrich, R.P., Chaurasia, G., Li, S., Hesse, F., Rechien, S.P., et al. (2015). Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Res. 25, 701–713.

The Huntington’s Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72, 971–983.

Uhlen, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardino- glu, A., Sivertsson, Å., Kampf, C., Stjöstedt, A., Asplund, A., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science 347, 1260419.

Vassart, J.P., and DiFiligo, M. (1998). Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369–384.

Walther, D.M., and Mann, M. (2011). Accurate quantification of more than 4000 mouse tissue proteomes reveals minimal proteome changes during aging. Mol. Cell. Proteomics 10, M110.004523.
Warringer, J., and Blomberg, A. (2006). Evolutionary constraints on yeast protein size. BMC Evol. Biol. 6, 61.

Winklhofer, K.F., Tatzelt, J., and Haass, C. (2008). The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27, 336–349.

Wisniewski, J.R., Hein, M.Y., Cox, J., and Mann, M. (2014). A “proteomic ruler” for protein copy number and concentration estimation without spike-in standards. Mol. Cell. Proteomics 13, 3497–3506.

Woodman, B., Butler, R., Landles, C., Lupton, M.K., Tse, J., Hockly, E., Moffitt, H., Sathasivam, K., and Bates, G.P. (2007). The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 72, 83–97.

Wytenbach, A., Swartz, J., Kita, H., Thykjaer, T., Carmichael, J., Bradley, J., Brown, R., Maxwell, M., Schapira, A., Orntoft, T.F., et al. (2001). Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington’s disease. Hum. Mol. Genet. 10, 1829–1845.
Supplemental Information

Spatiotemporal Proteomic Profiling
of Huntington's Disease Inclusions Reveals
Widespread Loss of Protein Function

Fabian Hosp, Sara Gutiérrez-Ángel, Martin H. Schaefer, Jürgen Cox, Felix Meissner, Mark S. Hipp, F.-Ulrich Hartl, Rüdiger Klein, Irina Dudanova, and Matthias Mann
**Hosp et al., Figure S1**

(A) The Pearson correlation of soluble proteomes of both R6/2 and wild-type (WT) mice for all brain regions across time is plotted as heatmap visualization. (B) Scatterplot of normalized label-free intensity for proteins quantified in the soluble striatal proteome of 5- or 12-week-old WT mice reveals only few changes in the brain proteome between these two age groups; Pearson correlation is indicated; data points colored by local point density.

**Figure S1. Reproducibility of total proteome measurements. Related to Figure 2.** (A) The Pearson correlation of soluble proteomes of both R6/2 and wild-type (WT) mice for all brain regions across time is plotted as heatmap visualization. (B) Scatterplot of normalized label-free intensity for proteins quantified in the soluble striatal proteome of 5- or 12-week-old WT mice reveals only few changes in the brain proteome between these two age groups; Pearson correlation is indicated; data points colored by local point density.
Figure S2. Loss of MSN-specific proteins. Related to Figure 3. (A) Differentially expressed proteins were identified by three-way ANOVA. Each dot represents a protein that the ANOVA finds significantly regulated for the indicated variables and combinations thereof. (B) Annotation matrix of protein attributes, such as complexes, gene ontologies and pathways highlights changes in the spatiotemporal composition of the soluble fraction; color code indicates the normalized median abundance of the proteins belonging to each category relative to the overall distribution of all proteins; selected annotations are highlighted; red most abundant, blue least abundant; Mann-Whitney U test (BH-FDR<0.05). (C) Grouping of top 20 candidates most similar to the Pde10a expression profile by protein function.
Figure S3. Quantification of HTT IBs from cortical and striatal tissue of R6/2 mice. Related to Figure 5. (A) Immunohistochemistry-based counting of inclusions from 5, 8 or 12-week-old R6/2 and WT mice; one-way ANOVA with Bonferroni’s multiple comparison test, * p<0.05, ** p<0.01, *** p<0.001; n=3. (B) Frequency distribution of the data in Fig. S3A; one-way ANOVA with Bonferroni’s multiple comparison test, * p<0.05, ** p<0.01, *** p<0.001; n=3. (C) Immunohistochemistry staining of cortical and striatal tissue of R6/2 mice; DAPI, blue; DARPP-32 for medium spiny neuron staining, green; EM48 for HTT inclusion staining, red; scale bar is 10 µm. (D) Representative single-plane immunofluorescence in a 12-week-old R6/2 striatum showing colocalization of PLP1 protein with IBs; Nissl staining for neurons, grey; EM48 staining for HTT IBs, red; PLP1 staining, green; asterisks mark white matter bundles of the striatum; scale bar is 20 µm. (E) Close-up of the colocalization; arrowheads point to PLP1 sequestered in IBs; arrows point to IBs without colocalization; scale bar is 10 µm.
Figure S4. Volcano plots of insoluble fractions. Related to Figure 5. (A-D) Enrichment of proteins in the insoluble fractions is plotted by Volcano plots of all brain regions for 5 weeks, (E) 5 weeks whole brain, (F-I) all brain regions for 8 weeks, (J) 8 weeks whole brain, (K-N) all brain regions for 12 weeks and (O) 12 weeks whole brain. Color coding as in Figure 5C.
Figure S5. Correlation of protein abundance. Related to Figure 5. Correlation of iBAQ copy numbers for both soluble and insoluble proteins from R6/2 mice across all brain regions and time points. Pearson correlation is indicated.
Hosp et al., Figure S6

Figure S6. Degree of protein sequestration. Related to Figure 5. (A) Boxplot of iBAQ values for the most up- or down-regulated proteins in the soluble proteome (clusters 1-4, Figure 3C) being sequestered to the insoluble fraction; one-way ANOVA with Bonferroni’s multiple comparison test, * p<0.05, ** p<0.01, *** p<0.001; n=3. (B-E) Sequence motif analyses across time; two-sided Mann-Whitney U test, * p<0.05, *** p<0.001. (F) Boxplots of all brain regions over time displaying the iBAQ ratio of proteins in the soluble over the insoluble fraction.

(A) Boxplot of iBAQ values for the most up- or down-regulated proteins in the soluble proteome (clusters 1-4, Figure 3C) being sequestered to the insoluble fraction; one-way ANOVA with Bonferroni’s multiple comparison test, * p<0.05, ** p<0.01, *** p<0.001; n=3. (B-E) Sequence motif analyses across time; two-sided Mann-Whitney U test, * p<0.05, *** p<0.001. (F) Boxplots of all brain regions over time displaying the iBAQ ratio of proteins in the soluble over the insoluble fraction.
Figure S7. Validation of candidates from the proteomic screen. Related to Figure 7. (A) Candidate selection. (B) Quantification of candidates in immunoblots of brain regions from 8- and 12-week-old R6/2 mice, normalized to WT controls (dotted line); Student’s t-test, *p<0.05; n=3-4. Striatal data is also shown in Figure 7. (C) Representative single-plane images of 12-week-old R6/2 striatum with nuclear hnRNPA2B1 accumulations; EM48 staining for HTT inclusion bodies, red; hnRNPA2B1, green; DARPP-32 staining for MSNs, blue; arrowheads, DARPP32+ neurons containing IBs and showing a nuclear accumulation of hnRNPA2B1; scale bar is 10 µm. (D) Examples of two DARPP32+ neurons showing colocalization (yellow) of hnRNPA2B1 with the IB; scale bar is 5 µm. (E) Quantification of nuclear accumulation of hnRNPA2B1 in DARPP32+ neurons with IB, in the striatum of 12-week-old R6/2 mice; there were significantly more neurons with than without hnRNPA2B1 accumulation. Student’s t-test, *p<0.001; n=3 mice; 7 image fields each. In all neurons with hnRNPA2B1 accumulation, which represent 62% of neurons containing IBs and showing a nuclear accumulation of hnRNPA2B1; scale bar is 10 µm. (F) Changes in the proteome of HD-Q74 between induced and non-induced cells.

(A) Number of IBs per cell in HD-Q74 cells transfected with the different candidates. (J) Number of IBs per cell in HD-Q74 cells transfected with the candidates; multiple two-tailed t-test with Benjamini-Hochberg correction; *FDR<0.05; n=3. (K) Log2FC in aggregation load as determined by quantification of slot blot assays of HD-Q74 cell lysates transfected with the candidates, anti-GFP staining; multiple two-tailed t-test with Benjamini-Hochberg correction; *FDR<0.05; normalized to mCherry transfection controls; n=3.
## Supplemental Experimental Procedures

### RESOURCE TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|----------------------|--------|------------|
| **Antibodies**       |        |            |
| Rabbit monoclonal anti-myc | Cell Signaling | Cat# 2278 |
| Rabbit polyclonal anti-myc | Sigma-Aldrich | Cat# C3956 |
| Rabbit monoclonal anti-flag | Sigma-Aldrich | Cat# F7425 |
| Rat monoclonal anti-HA | Sigma-Aldrich | Cat# 11867423001 |
| Rabbit polyclonal anti-HA | Sigma-Aldrich | Cat# H6908 |
| Rat monoclonal anti-GFP | Chromotek | Cat# 3h9 |
| Rabbit monoclonal anti-GAPDH | Cell Signaling | Cat# 2118 |
| Mouse monoclonal anti-Huntingtin | Milipore | Cat# MAB5374 |
| Rabbit monoclonal anti-DARPP-32 | Abcam | Cat# ab40801 |
| Mouse monoclonal anti-hnRNPA2B1 | Santa Cruz Biotechnology, Inc. | Cat# sc-374053 |
| Mouse monoclonal anti-KIF3B | Santa Cruz Biotechnology, Inc. | Cat# sc-514165 |
| Rabbit polyclonal anti-HSP90 | New England Biolabs GmbH | Cat# 4877 |
| Mouse monoclonal anti-β-Actin | Sigma-Aldrich | Cat# A5316 |
| Rabbit polyclonal anti-PLP1 | Abcam | Cat# ab28486 |
| NeuroTrace 640/660 Nissl Stain | Thermo Fisher Scientific | Cat# N21483 |
| Donkey polyclonal anti-Rabbit Cy2-conjugate | Jackson ImmunoResearch | Cat# 711-545-152 |
| Donkey polyclonal anti-Rabbit Cy3-conjugate | Jackson ImmunoResearch | Cat# 711-165-152 |
| Donkey polyclonal anti-Mouse Cy3-conjugate | Jackson ImmunoResearch | Cat# 711-165-151 |
| Anti-Rabbit IgG, HRP-linked | Cell Signaling | Cat# 7074 |
| **Chemicals, Peptides, and Recombinant Proteins** | Sigma-Aldrich | Cat#E1014 |
| Benzonase | Sigma-Aldrich | Cat# E1014 |
| Hygromycin B | Thermo Fisher Scientific | Cat# 10687010 |
| G418 | Thermo Fisher Scientific | Cat# 10131035 |
| Doxycycline | Sigma-Aldrich | Cat# D9891 |
| Item                                                                 | Supplier                              | Catalog Number |
|----------------------------------------------------------------------|---------------------------------------|----------------|
| **Lysyl Endopeptidase LysC**                                          | Wako Chemicals                        | Cat# 129-02541 |
| **Trypsin**                                                           | Sigma-Aldrich                         | Cat# T6567     |
| **Lipofectamine LTX with Plus Reagent**                              | Thermo Fisher Scientific              | Cat# 15338100  |
| **ProLong Gold antifade reagent**                                    | Life Technologies                    | Cat# P36930    |
| **Critical Commercial Assays**                                        |                                       |                |
| **Pierce LDH Cytotoxicity Assay Kit**                                 | Thermo Fisher Scientific              | Cat# 88953     |
| **Deposited Data**                                                    |                                       |                |
| **Proteomic dataset**                                                 | This study                            | ProteomeXchange PXD004973 |
| **Mouse UniprotKB/Swiss-Prot database (Mouse UniProt 2014-07)**      | N/A                                   | http://www.uniprot.org/proteomes |
| **Brain peptide library for MS matching**                            | (Sharma et al., 2015)                 | N/A            |
| **Experimental Models: Cell Lines**                                   |                                       |                |
| **Rat pheochromocytoma PC12 HDExon1-Q23**                             | Gift from David Rubensztein, (University of Cambridge, UK) | N/A            |
| **Rat pheochromocytoma PC12 HDExon1-Q74**                             | Gift from David Rubensztein, (University of Cambridge, UK) | N/A            |
| **Experimental Models: Organisms/Strains**                           |                                       |                |
| **R6/2 (B6CBA-Tg(HD exon1)62gpb/1J) female mice**                    | The Jackson Laboratory                | Stock No: 002810 |
| **Recombinant DNA**                                                   |                                       |                |
| **Plasmid C-term Myc + DDK_AARS**                                     | BioCat                                | RC202136-OR    |
| **Plasmid C-term Myc + DDK_AP2A2**                                    | BioCat                                | RC203018-OR    |
| **Plasmid C-term Myc + DDK_CACNB3**                                   | BioCat                                | RC207229-OR    |
| **Plasmid C-term Myc + DDK_CHMP3**                                    | BioCat                                | RC220006-OR    |
| **Plasmid C-term Myc + DDK_CNP**                                      | BioCat                                | RC207038-OR    |
| **Plasmid C-term Myc + DDK_DCTN1**                                    | BioCat                                | RC211975-OR    |
| **Plasmid C-term Myc + DDK_DNM1**                                     | BioCat                                | RC206284-OR    |
| **Plasmid C-term Myc + DDK_DPYSLL2**                                  | BioCat                                | RC231368-OR    |
| **Plasmid C-term Myc + DDK_HDG**                                      | BioCat                                | RC204148-OR    |
| **Plasmid C-term Myc + DDK_HNRNPA2B1**                                | BioCat                                | RC219318-OR    |
| **Plasmid N-term HA_HSP90AA1**                                        | Gift from William Sessa (Yale School of Medicine) | AddGene #22487 (Garcia-Cardena et al., 1998) |
| **Plasmid C-term Myc + DDK_INA**                                      | BioCat                                | RC202877-OR    |
| Plasmid C-term Myc + DDK_KIF3B | BioCat | RC213911-OR |
|--------------------------------|--------|-------------|
| Plasmid N-term mApple_MAPT     | Gift from Michael Davidson (National High Magnetic Field Laboratory) | AddGene #54924 |
| Plasmid C-term Myc + DDK_NCAM1| BioCat | RC207890-OR |
| Plasmid N-term HA_NFASC       | Gift from Vann Bennett (Duke University School of Medicine) | AddGene #31061 (Zhang et al., 1998) |
| Plasmid N-term Myc_RAC1       | Gift from Lawrence Kirschner (Ohio State University) | AddGene #37030 (Manchanda et al., 2013) |
| Plasmid C-term Myc + DDK_SBF1 | BioCat | RC222090-OR |
| Plasmid C-term Myc + DDK_SRGAP3| BioCat | RC214288-OR |
| Plasmid mCherry               | This study | N/A |

**Software and Algorithms**

| MaxQuant version 1.5.1.1        | (Cox and Mann, 2008) | [http://www.biochem.mpg.de5111795/maxquant](http://www.biochem.mpg.de5111795/maxquant) |
|---------------------------------|-----------------------|------------------------------------------------------------------|
| Perseus version 1.5.2.11         | (Tyanova et al., 2016b) | [http://www.biochem.mpg.de/5111810/perseus](http://www.biochem.mpg.de/5111810/perseus) |
| Coils                           | (Lupas et al., 1991)  | N/A                                                              |
| ImageJ version 1.49i            | NIH                  | N/A                                                              |

**CONTACT FOR REAGENT AND RESOURCE SHARING**

Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding authors Irina Dudanova (idudanova@neuro.mpg.de) or Matthias Mann (mmann@biochem.mpg.de).
METHOD DETAILS

CSF Extraction and Preparation of Mouse Brain Regions

Mice were euthanized by carbondioxide inhalation, then shaved between the shoulders and below the skull. Next, mice were placed prone on an in-house designed stereotaxic instrument and the skull was secured by ear bars. To collect CSF, a midsagittal incision of the skin was made posterior to the occipital crest. The subcutaneous tissue and occipital muscles were carefully removed. A sterile syringe fixed to the stereotaxic instrument was then carefully advanced towards the cisterna magna by a fraction of about one millimeter and CSF was slowly aspirated. This method typically allowed collection of 3-5 µl of CSF without visible signs of contaminating blood. Immediately after extraction, the CSF samples were flash-frozen in liquid nitrogen and stored at -80°C until further use. Directly after CSF extraction, whole brains were dissected from each mouse, washed once in ice-cold PBS and divided in halves by sagittal dissection on ice. One cerebral hemisphere was further dissected at 4°C in order to obtain the cerebellum, hippocampus, striatum and the cortex regions. Dissected brain regions were immediately flash-frozen in liquid nitrogen and stored at -80°C until further use.

MS Sample Preparation

Shortly before use, CSF was thawed on ice and centrifuged at 16,000 g at 4°C for 15 min to remove any potential contaminations. Clarified CSF was mixed with 40 µl denaturation buffer (6 M urea, 2 M thiourea, 10 mM Hepes pH 8.0) for subsequent in-solution digestion. Dissected brain regions were thawed on ice, placed in FastPrep-24 tubes filled with LysingMatrix D (MP Biomedicals, Eschwege, Germany) and mixed with RIPA buffer supplemented with protease inhibitors (Roche, Mannheim, Germany) and Benzonase (Sigma-Aldrich, Germany). Lysis was achieved by running six times for one min at 4.0 m/s, whereas samples were chilled on ice after each run for one min. Next, the lysed brain regions were separated into pellet and supernatant fraction by centrifugation at 16,000 g at 4°C for 15 min. Soluble proteins in the supernatant were quantified using a tryptophan fluorescence emission assay (Kulak et al., 2014). After protein concentration estimation, 200 µg protein lysate was precipitated for two hours at -20°C with ice-cold acetone. Samples were centrifuged at 16,000 g at 4°C for 20 min and the supernatant was discarded. The precipitated proteins were mixed with 80 µl denaturation buffer (6 M urea, 2 M thiourea, 10 mM Hepes pH
8.0) for subsequent in-solution digestion. The insoluble pellet fraction from the initial lysate clarification was boiled with 100 µl 2% SDS for 10 min at 95°C. After centrifugation at 16,000 g at 4°C for 10 min, the supernatant was discarded and the pellet was washed three times in 2% SDS and three times in PBS for 5 min at 1,000 rpm, followed by centrifugation after each step at 16,000 g at 4°C for 10 min. Next, the pellet fraction was incubated with 100 µl 90% formic acid at 37°C and 1,000 rpm for 45 min. Finally, the pellet samples were snap-frozen in liquid nitrogen and lyophilized overnight in a cold-trap centrifugal evaporator. The next morning, the samples were re-solubilized in 50 µl denaturation buffer (6 M urea, 2 M thiourea, 10 mM Hepes pH 8.0) for subsequent in-solution digestion.

For the in-solution digestion, proteins were digested by LysC (1:100 enzyme to protein ratio; Wako Chemicals, Japan) for three hours at 37°C, followed by trypsin (1:100 enzyme to protein ratio; Sigma-Aldrich) overnight at 37°C. All samples were finally desalted on SDB-RPS StageTips (3M, Empore, Neuss, Germany) and eluted as described (Kulak et al., 2014).

**MS Data Processing**

All data was analyzed using the MaxQuant software package 1.5.1.1 (Cox and Mann, 2008). The false discovery rate (FDR) cut-off was set to 1% for protein and peptide spectrum matches. Peptides were required to have a minimum length of 7 amino acids and a maximum mass of 4600 Da. MaxQuant was used to score fragmentation scans for identification based on a search with an initial allowed mass deviation of the precursor ion of a maximum of 4.5 ppm after time-dependent mass calibration. The allowed fragment mass deviation was 20 ppm. Fragmentation spectra were identified using the UniprotKB *Mus musculus* database (UniProt, 2015), based on the 2014_07 release, combined with 262 common contaminants by the integrated Andromeda search engine (Cox et al., 2011). Enzyme specificity was set as C-terminal to arginine and lysine, also allowing cleavage before proline, and a maximum of two missed cleavages. Carbamidomethylation of cysteine was set as fixed modification and N-terminal protein acetylation as well as methionine oxidation as variable modifications. Both ‘label-free quantification (MaxLFQ)’ with a minimum ratio count of 1 and ‘match between runs’ with standard settings were enabled (Cox et al., 2014). We used cell type- and brain region- resolved brain proteome data (Sharma et al., 2015) as additional library to gain matching peptide identifications (Tyanova et al., 2016a). Protein copy number estimates were calculated
using the iBAQ algorithm (Schwanhausser et al., 2011), in which the sum of all tryptic peptides intensities for each protein is divided by the number of theoretically observable peptides. Copy number ranking sorts values from the highest to the lowest value.

**MS Data Analysis and Visualization**

Basic data handling, normalization, statistics and annotation enrichment analysis was performed with the Perseus software package (Tyanova et al., 2016b). We filtered for 8,455 protein groups (soluble proteome), 778 proteinGroups (CSF) and 1495 proteinGroups (insoluble proteome) that were quantified with at least two valid values in at least one group of triplicates. CSF data was additionally filtered according to known GO annotations (CC_extracellular space; BP_secretion; BP_body fluid secretion) and an in-house curated human CSF dataset (unpublished). Missing values were imputed with values representing a normal distribution (generated at 1.8 standard deviations of the total intensity distribution, subtracted from the mean, and a width of 0.3 standard deviations). Volcano plots were generated as described (Keilhauer et al., 2015). Differentially expressed proteins were identified by three-way ANOVA test at a permutation-based FDR cutoff of 0.05. Pathway enrichment analysis was performed based on a Fisher exact test with a Benjamini-Hochberg FDR cutoff of 0.02. GOCC, GOBP, GOMF, CORUM, Pfam domains and KEGG pathway annotations were used for the analysis. The algorithm used for annotation matrix testing is based on a two-dimensional version of the nonparametric Mann-Whitney test, with a p-value threshold of 0.005 (Geiger et al., 2012). 1D annotation enrichment score was calculated on the basis of the protein expression fold change between WT and R6/2 sample groups (Cox and Mann, 2012). All sequence analyses of the mouse proteome were performed on the manually curated part of Uniprot (SwissProt) release 2015_03 (UniProt, 2015). For the prediction of coiled coils the tool ‘coils’ (Lupas et al., 1991) was used. The coiled coil probability cutoff was set to 0.8. PolyQ regions were determined by computationally scanning the *M. musculus* proteome for consecutive runs of glutamine of a minimum length of six residues (not allowing for any non-glutamine residues within). Prediction of low complexity regions was performed as described (Wootton and Federhen, 1993) with a minimal length of 35 residues.
**PC12 Cell Viability Assays and Biochemical Assays**

For the starvation assay, all serum was removed from the beginning of the experiment. Cells were seeded on coverslips in 24-well cell culture plates for both immunofluorescence microscopy studies and viability assays. After 12 h plated cells were transfected with either mCherry plasmid as control, or the different candidate’s plasmids and induced 5 h after transfection. All plasmid transfections were performed with Lipofectamine LTX with Plus Reagent (15338100, Thermo Fisher Scientific) according to manufacturer’s instructions. For viability studies, 50 µl of the medium from each well and each condition were taken at 60 h post-transfection. The LDH assay was performed according to manufacturer’s instructions (Pierce LDH cytotoxicity Assay Kit, Thermo Fisher Scientific) and absorbance was measured at 490 nm. Filter retardation assay was performed using slot-blotting essentially as described (Scherzinger et al., 1997) with primary antibodies against GFP (1:1,000, 3H9, Chromotek). For description of Western blotting, see Supplementary Experimental Procedures.

**Immunohistochemistry**

Brains of female R6/2 mice and control littermates of different ages were collected after transcardial perfusion with 4% paraformaldehyde in PBS, followed by overnight fixation. Whole brains were then embedded in albumin-gelatin medium (45% albumin, 1.5% gelatin, in 1 M sodium acetate pH 6.5) and sectioned on a vibratome 1000S (Leica). For some stainings, antigen retrieval was performed in 10 mM sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6) at 80°C for 30 min. Floating sections of 50 µm were permeabilized with 0.5% TritonX-100 for 20 min and then blocked for 2 hours with 0.2% BSA, 5% donkey serum, 0.2% lysine, 0.2% glycine in PBS and permeabilized again. Sections were incubated overnight at 4°C with primary antibodies against mHtt (EM48 1:500, MAB5374, Milipore), DARPP-32 (1:500, ab40801, Abcam), PLP1 (1:100, ab28486, Abcam), hnRNPA2B1 (1:100, sc-374053, SantaCruz Biotechnology) in 0.3% TritonX-100, 2% BSA in PBS, and washed three times with PBS. Sections were then incubated with Cy2-conjugated anti-rabbit (1:200, 711-545-152, Jackson ImmunoResearch), Cy3-conjugated anti-mouse (1:200, 715-165-151 Jackson ImmunoResearch) secondary antibodies and/or NeuroTrace 640/660 Nissl Stain (1:1000, N21483, Thermo Fisher Scientific). Nuclei were counterstained with 4’, 6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) and sections were mounted with Mowiol (in-house preparation).
PC12 cells were fixed 60 h post-transfection in 4% paraformaldehyde in PBS for 15 min, then permeabilized in 0.1% TritonX-100 for 5 min and washed three times in PBS. Blocking was performed for 30 min as described above. Coverslips were incubated for 1 h at room temperature with primary antibodies: anti-myc (1:250, 2278, Cell Signaling), anti-Flag (1:500, F7425, Sigma-Aldrich) and anti-HA (1:500, 11867423001, Roche) followed by Cy3-conjugated anti-rabbit secondary antibody (1:200, 711-165-152, Jackson ImmunoResearch). Nuclei were counterstained with DAPI (Sigma-Aldrich) and coverslips were mounted with ProLong Gold antifade reagent (P36930, Life Technologies). Sections and coverslips were examined at a Confocal TCS SP8 microscope (Leica). Images were taken using a 40x objective.

Aggregate Quantification in Cells and Tissues
Aggregates were quantified using an in-house macro on the freeware ImageJ version 1.49i (NIH). For R6/2 brain sections, aggregates were counted in 20 different confocal stacks in each brain region, in a total of 3 independent experiments. For PC12 cells, aggregates were analyzed in 20 different fields of view for each candidate, in a total of 3 independent experiments. For the quantification of cells with hnRNPA2B1 nuclear accumulation, images were analyzed with an in-house developed pipeline for CellProfiler™, in 20 different fields of view for each mouse brain, in a total of 3 R6/2 mouse brains. The fluorescence intensity analysis was performed with ImageJ. All quantifications were performed in a blinded setting.

Western Blotting
Dissected brain regions were homogenized in lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 2mM EDTA and protease inhibitor tablet (Roche). For SDS-PAGE, 100 µg of proteins were separated in a 10% gradient gel and transferred to a PVDF membrane. The membrane was blotted with the following primary antibodies: hnRNPA2B1 (1:500, sc-374053, Santa Cruz Biotechnology, Inc.), HSP90 (1:1000, 4877, New England Biolabs GmbH), KIF3B (1:500, sc-514165, Santa Cruz Biotechnology, Inc.), β-Actin (1:2500, A5316, Sigma-Aldrich). After incubation with HRP-conjugated secondary antibodies, the bound antibodies were visualized by chemiluminescence. The intensity of the bands was quantified by Image J software.
Tables

Table S1. Protein expression data for total proteome measurements. Related to Figure 2. Log₂ MaxLFQ intensities and iBAQ copy numbers of proteins detected in the total soluble proteome of R6/2 and WT mice for all brain regions and across time.

Table S2. Protein expression data for CSF measurements. Related to Figure 4. Log₂ MaxLFQ intensities and iBAQ copy numbers of proteins detected in the cerebrospinal fluid of R6/2 and WT mice for all brain regions and across time.

Table S3. Protein expression data of WT and R6/2 mice for insoluble proteome measurements. Related to Figure 5. Log₂ MaxLFQ intensities and iBAQ values of proteins detected in the total insoluble proteome of R6/2 and WT mice for all brain regions and across time. Sequence motives with corresponding lengths and iBAQ ratios for soluble/insoluble iBAQ values are annotated. T-test difference and -log₁₀ p-values for R6/2 against WT comparisons were calculated in Perseus.

Table S4. Information about follow-up candidates. Related to Figure 6. Details of function, localization and known linkage to neurodegenerative diseases are indicated.
Supplemental References

Cox, J., Hein, M.Y., Luber, C.A., Paron, I., Nagaraj, N., and Mann, M. (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Molecular & cellular proteomics : MCP 13, 2513-2526.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature biotechnology 26, 1367-1372.
Cox, J., and Mann, M. (2012). 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC bioinformatics 13 Suppl 16, S12.
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J.V., and Mann, M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. Journal of proteome research 10, 1794-1805.
Garcia-Cardena, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papapetropoulos, A., and Sessa, W.C. (1998). Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392, 821-824.
Geiger, T., Wehner, A., Schaab, C., Cox, J., and Mann, M. (2012). Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Molecular & cellular proteomics : MCP 11, M111 014050.
Keilhauer, E.C., Hein, M.Y., and Mann, M. (2015). Accurate protein complex retrieval by affinity enrichment mass spectrometry (AE-MS) rather than affinity purification mass spectrometry (AP-MS). Molecular & cellular proteomics : MCP 14, 120-135.
Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N., and Mann, M. (2014). Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nature methods 11, 319-324.
Lupas, A., Van Dyke, M., and Stock, J. (1991). Predicting coiled coils from protein sequences. Science 252, 1162-1164.
Manchanda, P.K., Jones, G.N., Lee, A.A., Pringle, D.R., Zhang, M., Yu, L., La Perle, K.M., and Kirschner, L.S. (2013). Rac1 is required for Prkar1a-mediated NF2 suppression in Schwann cell tumors. Oncogene 32, 3491-3499.
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G.P., Davies, S.W., Lehrach, H., and Wanker, E.E. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558.
Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., and Selbach, M. (2011). Global quantification of mammalian gene expression control. Nature 473, 337-342.
Sharma, K., Schmitt, S., Bergner, C.G., Tyanova, S., Kannaiyan, N., Manrique-Hoyos, N., Kongi, K., Cantuti, L., Hanisch, U.K., Philips, M.A., et al. (2015). Cell type- and brain region-resolved mouse brain proteome. Nat Neurosci.
Tyanova, S., Temu, T., and Cox, J. (2016a). The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nature protocols 11, 2301-2319.
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M.Y., Geiger, T., Mann, M., and Cox, J. (2016b). The Perseus computational platform for comprehensive analysis of (prote)omics data. Nature methods. UniProt, C. (2015). UniProt: a hub for protein information. Nucleic acids research 43, D204-212.
Wootton, J., and Federhen, S. (1993). Statistics of local complexity in amino acid sequences and sequence databases. Computers & chemistry 17, 149-163.
Zhang, X., Davis, J.Q., Carpenter, S., and Bennett, V. (1998). Structural requirements for association of neurofascin with ankyrin. The Journal of biological chemistry 273, 30785-30794.